SomaGenics, an RNA-focused biotechnology company, announced expansion of its intellectual property portfolio with issue of two new patents for its RNA analysis technologies (miR-ID® and RealSeq®) and European patent protection for its therapeutic short synthetic hairpin RNA (sshRNA) agents. MiR-ID®, ...
Read More »SomaGenics secures $1.8M in funding from NIH to further develop the Real-Seq® technology platform for small RNA sequencing
SomaGenics has been awarded a $1.8M two-year NIH SBIR Phase II grant to further develop its RealSeq®–AC technology for next-generation sequencing (NGS) of small RNAs such as microRNA. Real-Seq®-AC dramatically reduces bias in small RNA sequencing libraries compared to commercially ...
Read More »